Fundz

Dermata Therapeutics reported raising $3.5 Million in an initial SEC Form D filing, from an offering of $3.5 Million

PUBLIC · DRMASep 27, 2024

Amount Raised

$3.5 Million

$3.5 Million sold, per SEC Form D (first sale Sep 17, 2024)

Round Type

Seed

San DiegoBiotechnologyHealth CareTherapeutics

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Dermata Therapeutics that raised within 45 days of this round, from Fundz verified event records.

  • Blue Earth Therapeutics raised $77M (Series A) on October 31, 2024.
  • Archon Biosciences raised $20M (Seed) on October 30, 2024.
  • Tempero Bio raised $77M on October 30, 2024.
  • SynOx Therapeutics raised $92M (Series B) on October 30, 2024.
  • Pathos AI raised $62M (Series C) on October 29, 2024.
  • CrossBridge Bio raised $11M on October 29, 2024.

Who to call at Dermata Therapeutics, and when

A new round usually means Dermata Therapeutics is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Dermata Therapeutics raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Dermata Therapeutics, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Dermata Therapeutics. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Dermata Therapeutics

Location

San Diego, California, United States

About

Dermata Therapeutics, Inc. is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. The Company's lead product candidate, DMT310, is the Company's first product candidate being developed from its Spongilla technology platform and is currently being evaluated in a Phase 3 program. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Dermata Therapeutics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contactsChris N., Chief Development OfficerSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Dermata Therapeutics's next move

See what Strategic adds

Dermata Therapeutics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.